Biotech Sales Growth Seen Greater Than 20% for 2003, 2004 Says S&P Equity Analyst in New Study
Tuesday November 25, 1:19 pm ET
Building on Strengths in Cancer and Autoimmune Therapies, Biotech Firms Expanding Reach Into New Areas Such as SARS and West Nile
NEW YORK, Nov. 25 /PRNewswire/ -- Standard & Poor's equity analyst covering biotechnology companies has published his latest study of the segment, in which he foresees sales growth exceeding 20% for 2003 and 2004, remaining strong into 2005 and 2006. The survey, Industry Survey on Biotechnology, is published twice yearly by Standard & Poor's, a leading provider of independent investment research, ratings and indices.
"Growth catalysts for the next several years will include continued revenue gains for entrenched biotech medications, a ramp-up in sales of newly approved therapeutics, and a promising industry wide pipeline that should generate future approvals by the U.S. Food and Drug Administration," says Frank DiLorenzo, Biotechnology Analyst, Standard & Poor's Equity Research Services, and author of the survey.
"Although biotech companies have built a legacy in several major therapeutic areas, including cancer, autoimmune conditions, and infectious diseases, they are also branching out into other markets that have traditionally been the domain of big pharmaceutical firms. New therapeutic opportunities, such as treatments for severe acute respiratory syndrome (SARS) and West Nile virus, may also come to fruition over the next decade," concludes DiLorenzo.
Standard & Poor's Industry Survey on Biotechnology looks at the issues affecting the industry. These include the opening up of financial markets for smaller public and private firms in the industry, the brisk pace of M&A activity, and the impact of demographics and disease trends on demand for biotech therapeutics. In addition there is a look at drug developments from key players in the industry such as Amgen Inc. (Nasdaq: AMGN - News), Genentech Inc. (NYSE: DNA - News), and Millennium Pharmaceuticals (Nasdaq: MLNM - News).
Industry Survey on Biotechnology is part of the Standard & Poor's Industry Surveys series, produced by its senior equity analysts, that keeps a watchful eye on 51 U.S. industries, offering insights into trends and conditions that affect leading companies' market performance. Covering nearly 1,200 U.S. stocks, Standard & Poor's equity analysts have the largest U.S. equity research coverage counts among firms with no investment banking activities.
Standard & Poor's Industry Surveys provide a broad and fundamental overview of each industry's structure, its recent performance, and an analysis of trends that will influence it in the future. Each survey is organized into the following sections: Current Environment, Industry Profile/Industry Trends, How the Industry Operates, Key Industry Ratios and Statistics, How to Analyze a Company, Industry References, Comparative Company Analysis, and a Glossary of terms used in that industry. Both text and data are provided, as are references to additional sources of industry information. Two surveys on each industry are published each year.
biz.yahoo.com |
